Celltrion
Phone: +82-32-850-5000
E-mail: BusinessDevelopment@celltrion.com
Web: https://www.celltrion.com/
| Type | Public |
|---|---|
| Traded as | KRX: 068270 |
| Industry | Biopharmaceutical |
| Founded | 2002 (2002) |
| Founder | Jung Jin Seo |
| Headquarters | Yeonsu-gu, Incheon, South Korea |
| Area served | Worldwide |
| Key people | Jung Jin Seo, Chairman Woo Sung Kee, CEO |
| Products | Remsima™, Truxima™, Herzuma™, Biosimilar Drug |
| Revenue |  ₩828,917 million (2017) |
| Operating income | ₩517,385 million (2017) |
| Net income | ₩403,181 million (2017) |
| Total assets | ₩3,255,319 million (2017) |
| Total equity | ₩2,522,076 million (2017) |
| Owner | Celltrion Holdings Co., Ltd. (23.03%) Ion Investments B.V. (9.54%) National Pension Service (6.07%) |
| Subsidiaries | Celltrion Entertainment |
| Website | www.celltrion.com/en |
A leading force in the Korean pharmaceutical industry, Celltrion achieved what was thought impossible by launching the world’s first “antibody biosimilar” from a country with a relatively underdeveloped pharmaceutical sector. The company has pioneered numerous uncharted areas to stellar success, which it plans to follow up by continuing its growth as a global biopharmaceutical company with unique approaches to small molecule pharmaceuticals and new businesses such as the Ubiquitous-healthcare platform business.
For detailed contact information visit location pages below.
Celltrion's locations around the world
Asia
Clinical Trials sponsored by Celltrion
-
Celltrion완전한크론병프랑스, 칠면조, 체코, 그리스, 라트비아, 헝가리, 벨라루스, 이스라엘, 미국, 스페인, 불가리아, 세르비아, 크로아티아, 이탈리아, 독일, 인도, 일본, 멕시코, 몰도바 공화국, 페루, 폴란드, 루마니아, 러시아 연방, 슬로바키아, 남아프리카, 우크라이나
-
Celltrion모집하지 않고 적극적으로